Connection

Richard Silver to Aged

This is a "connection" page, showing publications Richard Silver has written about Aged.
Connection Strength

0.517
  1. PACK syndrome: A case series and review. Am J Med Sci. 2023 04; 365(4):321-328.
    View in: PubMed
    Score: 0.071
  2. Factors associated with oral hygiene practices among adults with systemic sclerosis. Int J Dent Hyg. 2014 Aug; 12(3):180-6.
    View in: PubMed
    Score: 0.038
  3. Factors associated with gingival inflammation among adults with systemic sclerosis. Int J Dent Hyg. 2014 Feb; 12(1):55-61.
    View in: PubMed
    Score: 0.036
  4. Effect of orofacial exercises on oral aperture in adults with systemic sclerosis. Disabil Rehabil. 2012; 34(1):84-9.
    View in: PubMed
    Score: 0.033
  5. Effect of a multi-faceted intervention on gingival health among adults with systemic sclerosis. Clin Exp Rheumatol. 2011 Mar-Apr; 29(2 Suppl 65):S26-32.
    View in: PubMed
    Score: 0.032
  6. Patterns of hospital admissions and emergency room visits among patients with scleroderma in South Carolina, USA. J Rheumatol. 2003 Jun; 30(6):1238-43.
    View in: PubMed
    Score: 0.018
  7. Hospital admissions, length of stay, charges, and in-hospital death among patients with systemic sclerosis. J Rheumatol. 2001 Sep; 28(9):2031-7.
    View in: PubMed
    Score: 0.016
  8. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis Rheumatol. 2019 12; 71(12):2059-2067.
    View in: PubMed
    Score: 0.014
  9. Randomized Controlled Trial to Evaluate an Internet-Based Self-Management Program in Systemic Sclerosis. Arthritis Care Res (Hoboken). 2019 03; 71(3):435-447.
    View in: PubMed
    Score: 0.014
  10. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. J Rheumatol. 2019 02; 46(2):176-183.
    View in: PubMed
    Score: 0.013
  11. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 2018 01 04; 378(1):35-47.
    View in: PubMed
    Score: 0.013
  12. Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension. Ann Am Thorac Soc. 2017 May; 14(5):682-689.
    View in: PubMed
    Score: 0.012
  13. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 106(4):106-113.
    View in: PubMed
    Score: 0.012
  14. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 09; 4(9):708-719.
    View in: PubMed
    Score: 0.011
  15. Systemic Sclerosis and Perceptions of Quality in Primary Care. Am J Med Sci. 2016 05; 351(5):447-51.
    View in: PubMed
    Score: 0.011
  16. Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. Arthritis Res Ther. 2016 Jan 20; 18:20.
    View in: PubMed
    Score: 0.011
  17. Eosinophilia-myalgia syndrome: a long-term follow-up study. South Med J. 1995 Sep; 88(9):953-8.
    View in: PubMed
    Score: 0.011
  18. Electron probe microanalysis of silicon and the role of the macrophage in proximal (capsule) and distant sites in augmentation mammaplasty patients. Plast Reconstr Surg. 1995 Mar; 95(3):513-9.
    View in: PubMed
    Score: 0.010
  19. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken). 2014 Mar; 66(3):489-95.
    View in: PubMed
    Score: 0.010
  20. Recognition of pulmonary hypertension in the rheumatology community: lessons from a Quality Enhancement Research Initiative. Clin Exp Rheumatol. 2014 Nov-Dec; 32(6 Suppl 86):S-21-7.
    View in: PubMed
    Score: 0.010
  21. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov; 72(11):1747-55.
    View in: PubMed
    Score: 0.009
  22. Differential regulation of cell functions by CSD peptide subdomains. Respir Res. 2013 Sep 08; 14:90.
    View in: PubMed
    Score: 0.009
  23. Tryptophan metabolism via the kynurenine pathway in patients with the eosinophilia-myalgia syndrome. Arthritis Rheum. 1992 Sep; 35(9):1097-105.
    View in: PubMed
    Score: 0.009
  24. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol. 2010 Jul; 37(7):1488-501.
    View in: PubMed
    Score: 0.007
  25. Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann Rheum Dis. 2010 Jun; 69(6):1220-6.
    View in: PubMed
    Score: 0.007
  26. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med. 1990 Mar 29; 322(13):874-81.
    View in: PubMed
    Score: 0.007
  27. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008 Jan 01; 177(1):91-8.
    View in: PubMed
    Score: 0.006
  28. Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis. J Rheumatol. 2007 Jun; 34(6):1277-82.
    View in: PubMed
    Score: 0.006
  29. Tumoral calcinosis presenting as adhesive capsulitis: case report and literature review. Arthritis Rheum. 1987 Apr; 30(4):455-9.
    View in: PubMed
    Score: 0.006
  30. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22; 354(25):2655-66.
    View in: PubMed
    Score: 0.006
  31. Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol. 2005 Oct; 32(10):1888-92.
    View in: PubMed
    Score: 0.005
  32. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol. 2005 May; 32(5):832-40.
    View in: PubMed
    Score: 0.005
  33. Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis. Clin Exp Rheumatol. 2004 Nov-Dec; 22(6):733-42.
    View in: PubMed
    Score: 0.005
  34. Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. Am J Physiol Lung Cell Mol Physiol. 2005 Jan; 288(1):L190-201.
    View in: PubMed
    Score: 0.005
  35. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol. 2003 Aug; 163(2):571-81.
    View in: PubMed
    Score: 0.005
  36. Is occupational organic solvent exposure a risk factor for scleroderma? Arthritis Rheum. 1998 Jun; 41(6):1111-8.
    View in: PubMed
    Score: 0.003
  37. The eosinophilia-myalgia syndrome: status of 205 patients and results of treatment 2 years after onset. Ann Intern Med. 1995 Jun 01; 122(11):851-5.
    View in: PubMed
    Score: 0.003
  38. Fasciitis (not scleroderma) following prolonged exposure to an organic solvent (trichloroethylene). J Rheumatol. 1994 Aug; 21(8):1567-70.
    View in: PubMed
    Score: 0.002
  39. Familial clustering of scleroderma spectrum disease. Am J Med. 1988 Jun; 84(6):1023-32.
    View in: PubMed
    Score: 0.002
  40. Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. Hematol Oncol. 1988 Jan-Mar; 6(1):7-12.
    View in: PubMed
    Score: 0.002
  41. Dipyridamole decreases platelet-derived growth factor levels in human serum. Arteriosclerosis. 1987 Mar-Apr; 7(2):152-8.
    View in: PubMed
    Score: 0.001
  42. Anticentromere antibody and immunoglobulin allotypes in scleroderma. Arch Dermatol. 1985 Mar; 121(3):339-44.
    View in: PubMed
    Score: 0.001
  43. Direct and indirect immunofluorescent findings in dermatomyositis. J Cutan Pathol. 1985 Feb; 12(1):18-27.
    View in: PubMed
    Score: 0.001
  44. Fibronectin distribution in nailfold biopsies of scleroderma (systemic sclerosis) patients. Acta Derm Venereol. 1985; 65(3):185-9.
    View in: PubMed
    Score: 0.001
  45. Epidermal nuclear immunofluorescence: serological correlations supporting an in vivo reaction. Br J Dermatol. 1985 Jan; 112(1):15-22.
    View in: PubMed
    Score: 0.001
  46. Immunofluorescence in skin specimens from three different biopsy sites in patients with scleroderma. Clin Exp Rheumatol. 1985 Jan-Mar; 3(1):11-6.
    View in: PubMed
    Score: 0.001
  47. Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders. Am J Med. 1984 Nov; 77(5):812-22.
    View in: PubMed
    Score: 0.001
  48. Immune complexes and antinuclear, antinucleolar, and anticentromere antibodies in scleroderma. J Am Acad Dermatol. 1984 Sep; 11(3):461-7.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.